Event timezone:
My timezone:
Delivered Digitally on 25 - 26 May 2021
Anglonordic will be delivered digitally this year and is ordinarily exclusively for European investors and R&D companies from the Nordics and the UK to connect with each other. This year we're excited that we can extend our reach to a global audience. So if you're interested in the Nordic and UK Lifescience sector contact us to find out how you can get involved here.
With an established format of panel discussions, parallel technology and biotech investment digital rooms, plus 1:1 video meetings, this conference provides exceptional value. Investors with funds attend free-of-charge.
The Anglonordic Life Science Conference has a “by-invitation-only” policy. The organisers welcome a limited number of service suppliers as sponsors or exhibitors. To request an invitation click here.
This year the Conference Supported Charity will be Brain Tumour Research.
Why attend Anglonordic?
MEET decision makers at leading and upcoming drug discovery and technology companies from the UK and Nordic regions, along with investment firms from throughout Europe
LEARN from major investment firms about the current status of European investment in life science technologies
GAIN insights from experienced life science operators within the Anglo-Nordic space
The conference has a biotech investment focus; and a parallel technology investment focus featuring devices, diagnostics, delivery and development tools. One-to-one meetings take place from the 25 - 28 May. They'll be the opportunity to meet online with our Exhibitors and sponsors plus network in our breakout sessions.
One-to-one partnering meetings are pre-booked using the globally-renowned Meeting Mojo booking platform. Registered delegates can log in to browse profiles, set their own availability, request meetings, and promote their company to best advantage.
What our delegates say...
“Anglonordic is a great event to meet quality investors and companies - it is very well run and also includes panels covering interesting topics” Tim Luker, VP Emerging Technology & Innovation, Eli Lilly.
"This was a great meeting, content quality and organisation."
"Some very good panels and topics, good quality investors and companies"
"The conference is a fantastic event to meet new contacts, given the invitation only status it is well attended with quality investors and companies"
Platinum |
Gold |
Silver |
Supporting |
Over 80 investors confirmed so far including:
4BIO, Advent Life Science, Albion Technology & General VCT, Alpha Blue Ocean, Alpha Bronze Life Sciences Opportunities Fund, Apollo Ventures, Aratus Capital, Arix Bioscience, Arvic AG, Axilium Holding, Axon Capital Partners, Bioscience Managers, Biotechnology Business Institute, Bond Asian Ventures, Cascara Ventures Bvba, Catapult Ventures, Curam Capital Management, DeBere Capital Partners, Deep Science Ventures, Eli Lilly, ESM Biotech, Esperante, GIMV, GL Capital, GSK, GreenSky Capital, Helsinn Investment Fund, Hermes Partners Intl, i2020 Accelerator, Ignite Capital Partners, Inkef Capital, Innovate UK, Inveready Asset Management, IP Group, IPF Partners, Julz, Kreos Capital, Kurma Partners, Longacre Funding Partners, Lundbeckfonden Emerge, Lundbeckfonden Ventures, Luminous Ventures, M Ventures, Mercia Asset Management, Momentum Biotech, MVM Partners, NeoMed, Newables, Norgine Ventures, Novalis Biotech Acceleration, NRW.BANK, o2h Ventures, Optum Ventures, oxford technology 3, Panakes Partners, Pontifax, Questra, Rosetta Capital, RBV Capital - R-Pharm, Seroba Life Sciences, Seventure Partners, SHS, Swelife International, Syncona, Syndicate Room, Trilantic Europe, UCB Ventures, UK Innovation & Science Seed Fund, V-Bio Ventures, Vickers Venture Partners, Xeraya Capital and XOventure.
To view our 2019 Conference Programme and Attendees, click here.
